<h3>享受 TipRanks Premium 50% 折扣，放心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>來自先聲藥業（HK:2096）的最新更新已發佈。</p>
<p>先聲藥業已獲得中國國家藥品監督管理局的批准，開始針對局部晚期或轉移性實體瘤患者的獨立開發的雙特異性抗體藥物結合物 SIM0610 的臨牀試驗。SIM0610 旨在通過細胞內釋放拓撲異構酶 I 抑制劑誘導腫瘤細胞凋亡，並解決藥物耐受機制，特別是對 EGFR 酪氨酸激酶抑制劑的耐藥性；前臨牀數據已顯示在多個腫瘤模型中具有顯著的抗腫瘤活性，突顯了先聲在加強其腫瘤學管線和在靶向癌症治療中的競爭地位方面的努力。</p>
<p>（HK:2096）股票的最新分析師評級為買入，目標價為 16.30 港元。要查看先聲藥業股票的完整分析師預測列表，請參見 HK:2096 股票預測頁面。</p>
<p><strong>關於先聲藥業的更多信息</strong></p>
<p>先聲藥業是一家以創新和研發為驅動的製藥公司，已建立國家重點神經病學和腫瘤藥物開發實驗室。它專注於神經科學、腫瘤學、自身免疫疾病和抗感染領域的治療，並在具有顯著未來臨牀需求的疾病領域追求前瞻性發展，得益於內部研究和與創新公司及研究機構的戰略合作。</p>
<p><strong>平均交易量：</strong> 8,403,511</p>
<p><strong>技術情緒信號：</strong> 買入</p>
<p><strong>當前市值：</strong> 340.3 億港元</p>

先聲藥業

<p>先聲藥業集團有限公司已獲得中國國家藥品監督管理局的批准，開始針對 SIM0610 的臨牀試驗，這是一種針對 EGFR 和 cMET 的新型癌症藥物。該雙特異性抗體藥物偶聯物旨在誘導腫瘤細胞凋亡並解決藥物耐藥性。臨牀前數據表明其具有顯著的抗腫瘤活性，增強了先聲藥業的腫瘤學產品線。該股票評級為 “買入”，目標價為 16.30 港元</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>The latest update is out from Simcere Pharmaceutical Group Limited ( (HK:2096) ).</p>
<div class="lb-trans"><p>來自先聲藥業（HK:2096）的最新更新已發佈。</p>
</div><p>Simcere Pharmaceutical Group Limited has received approval from China’s National Medical Products Administration to begin clinical trials for SIM0610, an independently developed bispecific antibody-drug conjugate targeting EGFR and cMET in patients with locally advanced or metastatic solid tumors. SIM0610 is designed to induce tumor cell apoptosis via intracellular release of a topoisomerase I inhibitor and to address drug resistance mechanisms, particularly resistance to EGFR tyrosine kinase inhibitors; preclinical data have shown significant anti-tumor activity across multiple tumor models, underscoring Simcere’s push to strengthen its oncology pipeline and competitive position in targeted cancer therapies.</p>
<div class="lb-trans"><p>先聲藥業已獲得中國國家藥品監督管理局的批准，開始針對局部晚期或轉移性實體瘤患者的獨立開發的雙特異性抗體藥物結合物 SIM0610 的臨牀試驗。SIM0610 旨在通過細胞內釋放拓撲異構酶 I 抑制劑誘導腫瘤細胞凋亡，並解決藥物耐受機制，特別是對 EGFR 酪氨酸激酶抑制劑的耐藥性；前臨牀數據已顯示在多個腫瘤模型中具有顯著的抗腫瘤活性，突顯了先聲在加強其腫瘤學管線和在靶向癌症治療中的競爭地位方面的努力。</p>
</div><p>The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.</p>
<div class="lb-trans"><p>（HK:2096）股票的最新分析師評級為買入，目標價為 16.30 港元。要查看先聲藥業股票的完整分析師預測列表，請參見 HK:2096 股票預測頁面。</p>
</div><p><strong>More about Simcere Pharmaceutical Group Limited</strong></p>
<div class="lb-trans"><p><strong>關於先聲藥業的更多信息</strong></p>
</div><p>Simcere Pharmaceutical Group Limited is an innovation- and R&amp;D-driven pharmaceutical company that has established a State Key Laboratory of Neurology and Oncology Drug Development. It focuses on therapies in neuroscience, oncology, autoimmune diseases and anti-infective areas, and pursues forward-looking development in disease areas with significant future clinical needs, supported by in-house research and strategic partnerships with innovative companies and research institutes.</p>
<div class="lb-trans"><p>先聲藥業是一家以創新和研發為驅動的製藥公司，已建立國家重點神經病學和腫瘤藥物開發實驗室。它專注於神經科學、腫瘤學、自身免疫疾病和抗感染領域的治療，並在具有顯著未來臨牀需求的疾病領域追求前瞻性發展，得益於內部研究和與創新公司及研究機構的戰略合作。</p>
</div><p><strong>Average Trading Volume:</strong> 8,403,511</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 8,403,511</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技術情緒信號：</strong> 買入</p>
</div><p><strong>Current Market Cap:</strong> HK$34.03B</p>
<div class="lb-trans"><p><strong>當前市值：</strong> 340.3 億港元</p>
</div>

先聲藥業獲得國家藥品監督管理局（NMPA）的批准，開始進行新型 EGFR/cMET 癌症藥物的臨牀試驗